LifeActive Bio names cardiologist John L. Jefferies to board

LifeActive Bio has appointed internationally recognized cardiologist and healthcare innovator Dr. John L. Jefferies to its board of directors as it pushes its XnanodeX delivery platform across multiple markets. The move adds medical, research and business expertise as the company explores applications in defense, personal care, pharmaceuticals, wellness and potentially aerospace.

Why it matters: - LifeActive Bio is trying to position XnanodeX™ as a broad platform, not a single product. - Adding Dr. John L. Jefferies gives the company board-level expertise in cardiology, research, precision medicine, artificial intelligence and healthcare innovation. - The appointment supports LifeActive Bio’s push to develop and commercialize technologies with applications across several industries.

What happened: - LifeActive Bio announced the appointment of John L. Jefferies, M.D., M.P.H., M.B.A., to its board of directors on Aug. 18, 2026. - The company said Jefferies will provide strategic and scientific perspective as LifeActive Bio advances XnanodeX™ and evaluates opportunities across multiple markets. - Dex Morris, LifeActive Bio founder and CEO, said Jefferies brings clinical expertise, research leadership, technology innovation and business experience to the board.

The details: - LifeActive Bio describes itself as a platform technology company built around its proprietary XnanodeX™ delivery platform. - The company says its technology has potential applications in defense and human performance, personal care, pharmaceuticals, wellness and potentially aerospace. - XnanodeX™ is designed to expand how active compounds are delivered and utilized across a range of applications. - Jefferies is an internationally recognized cardiologist who specializes in cardiomyopathies, heart failure, genetics, heritable and rare diseases, precision medicine and artificial intelligence. - He has authored or co-authored more than 320 peer-reviewed manuscripts and book chapters. - Jefferies serves as lead editor of two cardiology textbooks. - His research has received funding from the National Institutes of Health and multiple industry partners. - Jefferies is a professor in the School of Public Health at the University of Memphis. - He is the immediate past governor of the Tennessee Chapter of the American College of Cardiology and the immediate past president of the American Heart Association Mid-South region. - He completed adult and pediatric cardiology fellowship training through Baylor College of Medicine, Texas Children's Hospital and the Texas Heart Institute. - Jefferies holds an MPH in Epidemiology from the University of Kentucky and an MBA from the Wharton School of the University of Pennsylvania. - He has served as a key opinion leader for more than 30 national and international companies and has sat on numerous scientific advisory boards. - He has also held senior medical and scientific leadership roles in healthcare industry organizations. - LifeActive Bio’s long-term strategy centers on building an intellectual property and technology ecosystem that can support multiple applications and commercial pathways. - The company says it is exploring partnership, licensing and application-specific development opportunities around the platform. - LifeActive Bio’s website is LifeActiveBio.com.

Between the lines: - The board move signals that LifeActive Bio is leaning into credibility and commercialization at the same time. - Jefferies’ background bridges clinical medicine and emerging technology, which fits a company trying to sell a platform story to investors, partners and future licensees. - The company is framing its value around optionality, with one core technology aimed at many markets rather than one lead product.

What's next: - LifeActive Bio will continue evaluating where XnanodeX™ can create the greatest impact, according to Jefferies and the company. - The company is expected to keep building partnerships and licensing relationships around the platform. - Jefferies will help guide strategic and scientific priorities as LifeActive Bio develops the technology for future commercial use.

The bottom line: - LifeActive Bio is adding senior medical firepower as it tries to turn XnanodeX™ into a multi-market platform with commercial upside.